Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F McAuliffe

Showing results (111-120 of 114) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 114 results.
Cancer Letters|March 14, 2026
Identification of the MRTFA/SRF pathway as a critical regulator of quiescence and chemotherapy resistance in cancerSantiago Panesso-Gómez, Alexander J Cole, Austin Arrigo, et al.
Cancer Cell|April 17, 2026
Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progressionTriet Minh Bui, Ernesto Rojas Jimenez, Zheqi Li, et al.
JAMA|December 12, 2024
Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical TrialE Shelley Hwang, Terry Hyslop, Thomas Lynch, et al.
Cancer Cell|November 18, 2022
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohortsSiri H Strand, Belén Rivero-Gutiérrez, Kathleen E Houlahan, et al.
Pageof 12

Showing results (111-120 of 114) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 114 results.
Cancer Letters|March 14, 2026
Identification of the MRTFA/SRF pathway as a critical regulator of quiescence and chemotherapy resistance in cancerSantiago Panesso-Gómez, Alexander J Cole, Austin Arrigo, et al.
Cancer Cell|April 17, 2026
Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progressionTriet Minh Bui, Ernesto Rojas Jimenez, Zheqi Li, et al.
JAMA|December 12, 2024
Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical TrialE Shelley Hwang, Terry Hyslop, Thomas Lynch, et al.
Cancer Cell|November 18, 2022
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohortsSiri H Strand, Belén Rivero-Gutiérrez, Kathleen E Houlahan, et al.
Pageof 12